High Efficacy of 14‐Day Triple Therapy‐Based, Bismuth‐Containing Quadruple Therapy for Initial <i>Helicobacter pylori</i> Eradication

Abstract

Addition bismuth and prolonging treatment duration can overcome H. pylori resistance to clarithromycin and decrease the bacterial load. Fourteen-day triple therapy-based, bismuth-containing quadruple therapy achieved ITT success rate 93% and could be recommended as the first line eradication regimen.